| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 35 | 2025 | 303 | 7.330 |
Why?
|
| Coronary Artery Disease | 34 | 2025 | 896 | 5.520 |
Why?
|
| Coronary Artery Bypass | 19 | 2024 | 535 | 3.820 |
Why?
|
| ST Elevation Myocardial Infarction | 15 | 2024 | 121 | 3.640 |
Why?
|
| Transcatheter Aortic Valve Replacement | 15 | 2024 | 221 | 2.930 |
Why?
|
| Acute Coronary Syndrome | 13 | 2025 | 244 | 2.930 |
Why?
|
| Coronary Angiography | 22 | 2025 | 485 | 2.720 |
Why?
|
| Aortic Valve Stenosis | 14 | 2024 | 358 | 2.720 |
Why?
|
| Drug-Eluting Stents | 7 | 2019 | 70 | 2.230 |
Why?
|
| Myocardial Infarction | 21 | 2025 | 1068 | 2.100 |
Why?
|
| Hospital Mortality | 16 | 2025 | 1100 | 2.010 |
Why?
|
| Cardiac Tamponade | 3 | 2024 | 38 | 1.720 |
Why?
|
| Stroke | 17 | 2024 | 1079 | 1.640 |
Why?
|
| Coronary Stenosis | 5 | 2025 | 81 | 1.570 |
Why?
|
| Coronary Vessels | 10 | 2025 | 540 | 1.460 |
Why?
|
| Treatment Outcome | 63 | 2025 | 13103 | 1.410 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2012 | 184 | 1.400 |
Why?
|
| Electrocardiography | 8 | 2024 | 997 | 1.390 |
Why?
|
| Atrial Fibrillation | 9 | 2024 | 699 | 1.360 |
Why?
|
| Peripheral Arterial Disease | 6 | 2025 | 321 | 1.320 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 906 | 1.240 |
Why?
|
| Risk Factors | 53 | 2025 | 10951 | 1.210 |
Why?
|
| Postoperative Complications | 14 | 2024 | 3171 | 1.180 |
Why?
|
| Registries | 11 | 2023 | 1581 | 1.170 |
Why?
|
| Myocardial Revascularization | 7 | 2024 | 107 | 1.170 |
Why?
|
| Humans | 166 | 2025 | 133331 | 1.160 |
Why?
|
| Heart Valve Prosthesis Implantation | 9 | 2024 | 460 | 1.150 |
Why?
|
| Ventricular Dysfunction, Left | 6 | 2020 | 376 | 1.040 |
Why?
|
| Pericardium | 2 | 2024 | 87 | 1.030 |
Why?
|
| Stents | 7 | 2025 | 881 | 1.020 |
Why?
|
| Pericardial Effusion | 3 | 2024 | 70 | 1.020 |
Why?
|
| Shock, Cardiogenic | 8 | 2025 | 212 | 1.010 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2024 | 292 | 1.000 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2025 | 1163 | 0.990 |
Why?
|
| Cardiovascular Diseases | 15 | 2024 | 2092 | 0.980 |
Why?
|
| Aged | 57 | 2025 | 21497 | 0.960 |
Why?
|
| Myxoma | 1 | 2025 | 29 | 0.920 |
Why?
|
| Metal Nanoparticles | 2 | 2022 | 59 | 0.920 |
Why?
|
| Esophageal Fistula | 1 | 2024 | 15 | 0.910 |
Why?
|
| Atrial Appendage | 2 | 2022 | 51 | 0.900 |
Why?
|
| Coronary Vessel Anomalies | 7 | 2024 | 288 | 0.880 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2024 | 760 | 0.870 |
Why?
|
| Heart Neoplasms | 1 | 2025 | 105 | 0.860 |
Why?
|
| Middle Aged | 58 | 2025 | 28977 | 0.850 |
Why?
|
| Catheterization, Peripheral | 2 | 2023 | 132 | 0.830 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2021 | 251 | 0.810 |
Why?
|
| Ultrasonography, Interventional | 5 | 2024 | 207 | 0.800 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2023 | 32 | 0.800 |
Why?
|
| Cystitis | 1 | 2023 | 51 | 0.790 |
Why?
|
| Daucus carota | 1 | 2022 | 3 | 0.780 |
Why?
|
| Zinc Oxide | 1 | 2022 | 12 | 0.780 |
Why?
|
| Fibrinolytic Agents | 3 | 2024 | 209 | 0.770 |
Why?
|
| Risk Assessment | 19 | 2025 | 3718 | 0.770 |
Why?
|
| Male | 81 | 2025 | 65576 | 0.760 |
Why?
|
| Aortic Valve | 11 | 2024 | 467 | 0.730 |
Why?
|
| Cardiac Catheterization | 10 | 2023 | 669 | 0.730 |
Why?
|
| Fractional Flow Reserve, Myocardial | 4 | 2025 | 55 | 0.730 |
Why?
|
| Pericardiocentesis | 1 | 2021 | 17 | 0.720 |
Why?
|
| Atherosclerosis | 7 | 2024 | 1002 | 0.720 |
Why?
|
| Vascular Diseases | 4 | 2024 | 156 | 0.710 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 129 | 0.710 |
Why?
|
| Angioplasty, Balloon | 1 | 2022 | 162 | 0.710 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 214 | 0.700 |
Why?
|
| Thoracic Injuries | 1 | 2021 | 93 | 0.690 |
Why?
|
| Female | 81 | 2025 | 71482 | 0.680 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2022 | 157 | 0.670 |
Why?
|
| Echocardiography | 9 | 2021 | 1127 | 0.670 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 25 | 0.660 |
Why?
|
| Heart Transplantation | 2 | 2021 | 887 | 0.660 |
Why?
|
| Ultrasonic Therapy | 1 | 2019 | 29 | 0.630 |
Why?
|
| Stroke Volume | 6 | 2023 | 527 | 0.620 |
Why?
|
| Drug Utilization | 2 | 2020 | 169 | 0.620 |
Why?
|
| Cause of Death | 4 | 2024 | 504 | 0.620 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 1213 | 0.620 |
Why?
|
| Colchicine | 3 | 2021 | 39 | 0.610 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 548 | 0.600 |
Why?
|
| Hemorrhage | 8 | 2025 | 519 | 0.600 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 3 | 2025 | 19 | 0.580 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 121 | 0.580 |
Why?
|
| Seasons | 3 | 2005 | 328 | 0.580 |
Why?
|
| United States | 31 | 2025 | 11721 | 0.570 |
Why?
|
| Heart Septum | 2 | 2009 | 55 | 0.560 |
Why?
|
| Inpatients | 5 | 2022 | 551 | 0.560 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 7139 | 0.550 |
Why?
|
| Pericarditis | 2 | 2020 | 43 | 0.540 |
Why?
|
| Time Factors | 17 | 2025 | 6544 | 0.530 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 190 | 0.520 |
Why?
|
| Cocaine | 1 | 2018 | 208 | 0.520 |
Why?
|
| Ethanol | 2 | 2009 | 166 | 0.510 |
Why?
|
| Retrospective Studies | 27 | 2025 | 17568 | 0.510 |
Why?
|
| Anticoagulants | 6 | 2025 | 628 | 0.500 |
Why?
|
| Femoral Artery | 4 | 2023 | 192 | 0.500 |
Why?
|
| Thrombosis | 1 | 2021 | 545 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2023 | 806 | 0.480 |
Why?
|
| Catheter Ablation | 2 | 2009 | 248 | 0.460 |
Why?
|
| Propensity Score | 3 | 2021 | 263 | 0.460 |
Why?
|
| Robotic Surgical Procedures | 1 | 2019 | 234 | 0.450 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 154 | 0.450 |
Why?
|
| Obesity | 5 | 2024 | 2440 | 0.440 |
Why?
|
| Heart Failure | 8 | 2025 | 2428 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 4 | 2024 | 1340 | 0.420 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2014 | 112 | 0.420 |
Why?
|
| Conservative Treatment | 2 | 2025 | 42 | 0.410 |
Why?
|
| Drug Prescriptions | 5 | 2020 | 244 | 0.400 |
Why?
|
| Hypertension | 5 | 2023 | 1403 | 0.400 |
Why?
|
| Hyperlipidemias | 3 | 2024 | 199 | 0.390 |
Why?
|
| Tomography, Optical Coherence | 3 | 2024 | 572 | 0.390 |
Why?
|
| Saphenous Vein | 1 | 2012 | 61 | 0.370 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2023 | 182 | 0.370 |
Why?
|
| Adult | 32 | 2024 | 31674 | 0.370 |
Why?
|
| Sex Factors | 7 | 2021 | 1353 | 0.370 |
Why?
|
| Vascular Grafting | 1 | 2012 | 48 | 0.370 |
Why?
|
| Incidental Findings | 2 | 2009 | 129 | 0.350 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 492 | 0.350 |
Why?
|
| Cardiovascular Agents | 2 | 2025 | 90 | 0.350 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 783 | 0.350 |
Why?
|
| Logistic Models | 5 | 2021 | 1864 | 0.350 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 225 | 0.340 |
Why?
|
| Acute Kidney Injury | 3 | 2023 | 706 | 0.330 |
Why?
|
| Heart-Assist Devices | 3 | 2025 | 1098 | 0.330 |
Why?
|
| Feces | 2 | 2005 | 783 | 0.330 |
Why?
|
| Sex Characteristics | 1 | 2012 | 335 | 0.320 |
Why?
|
| Renal Insufficiency | 2 | 2011 | 256 | 0.320 |
Why?
|
| Severity of Illness Index | 10 | 2025 | 3105 | 0.320 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2013 | 295 | 0.320 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 542 | 0.310 |
Why?
|
| Heart Valve Prosthesis | 2 | 2023 | 314 | 0.310 |
Why?
|
| Odds Ratio | 4 | 2020 | 1253 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 772 | 0.300 |
Why?
|
| Sclerotherapy | 1 | 2009 | 41 | 0.300 |
Why?
|
| Vena Cava, Superior | 1 | 2009 | 59 | 0.300 |
Why?
|
| Tyrosine | 1 | 2009 | 157 | 0.290 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 120 | 0.290 |
Why?
|
| Sarcoidosis | 1 | 2009 | 59 | 0.290 |
Why?
|
| Heart Diseases | 2 | 2024 | 519 | 0.290 |
Why?
|
| Survival Rate | 6 | 2024 | 2207 | 0.280 |
Why?
|
| Heart Arrest | 2 | 2023 | 376 | 0.280 |
Why?
|
| Molecular Docking Simulation | 3 | 2022 | 127 | 0.270 |
Why?
|
| Age Factors | 4 | 2025 | 2956 | 0.270 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 138 | 0.260 |
Why?
|
| Carotid Artery Diseases | 2 | 2023 | 148 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2020 | 343 | 0.250 |
Why?
|
| Databases, Factual | 7 | 2025 | 1240 | 0.250 |
Why?
|
| Warfarin | 3 | 2022 | 134 | 0.250 |
Why?
|
| Pakistan | 9 | 2009 | 95 | 0.250 |
Why?
|
| Comorbidity | 8 | 2024 | 1622 | 0.250 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 1165 | 0.240 |
Why?
|
| Coronary Circulation | 2 | 2019 | 206 | 0.240 |
Why?
|
| Spasm | 2 | 2023 | 48 | 0.240 |
Why?
|
| Radial Artery | 2 | 2023 | 30 | 0.240 |
Why?
|
| Computed Tomography Angiography | 2 | 2025 | 214 | 0.240 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 5443 | 0.240 |
Why?
|
| Diastole | 3 | 2020 | 177 | 0.240 |
Why?
|
| Morbidity | 2 | 2019 | 255 | 0.240 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2025 | 47 | 0.230 |
Why?
|
| Pneumopericardium | 1 | 2024 | 4 | 0.230 |
Why?
|
| Guideline Adherence | 4 | 2020 | 395 | 0.230 |
Why?
|
| Hirudins | 1 | 2025 | 40 | 0.230 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 53 | 0.230 |
Why?
|
| Embolic Protection Devices | 1 | 2024 | 9 | 0.230 |
Why?
|
| Hematoma | 2 | 2023 | 94 | 0.230 |
Why?
|
| Ischemia | 2 | 2025 | 382 | 0.220 |
Why?
|
| Vibrio cholerae | 1 | 2004 | 29 | 0.220 |
Why?
|
| Life Style | 3 | 2023 | 459 | 0.220 |
Why?
|
| Cholera | 1 | 2004 | 30 | 0.220 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 74 | 0.220 |
Why?
|
| Fistula | 1 | 2024 | 54 | 0.220 |
Why?
|
| Mitral Valve | 2 | 2023 | 270 | 0.220 |
Why?
|
| Global Burden of Disease | 1 | 2024 | 32 | 0.220 |
Why?
|
| Intracranial Embolism | 1 | 2024 | 31 | 0.220 |
Why?
|
| Vascular Calcification | 1 | 2025 | 69 | 0.220 |
Why?
|
| Tumor Burden | 1 | 2025 | 256 | 0.220 |
Why?
|
| Simvastatin | 1 | 2024 | 77 | 0.220 |
Why?
|
| Prognosis | 9 | 2022 | 5044 | 0.220 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2005 | 92 | 0.220 |
Why?
|
| Plant Extracts | 2 | 2022 | 138 | 0.220 |
Why?
|
| Thiophenes | 2 | 2014 | 72 | 0.220 |
Why?
|
| Prevalence | 7 | 2024 | 2628 | 0.220 |
Why?
|
| Heart Valve Diseases | 2 | 2017 | 181 | 0.210 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2010 | 237 | 0.210 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 510 | 0.210 |
Why?
|
| Secondary Prevention | 3 | 2021 | 223 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2024 | 2205 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2021 | 1713 | 0.210 |
Why?
|
| Models, Cardiovascular | 1 | 2025 | 186 | 0.210 |
Why?
|
| Prescription Drugs | 2 | 2014 | 59 | 0.210 |
Why?
|
| Atrioventricular Block | 1 | 2024 | 41 | 0.210 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2025 | 258 | 0.210 |
Why?
|
| Predictive Value of Tests | 7 | 2025 | 2288 | 0.210 |
Why?
|
| Heparin | 1 | 2025 | 230 | 0.210 |
Why?
|
| Mortality | 5 | 2024 | 261 | 0.210 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2024 | 105 | 0.200 |
Why?
|
| Hemodynamics | 2 | 2025 | 858 | 0.200 |
Why?
|
| Coronary Occlusion | 1 | 2023 | 29 | 0.200 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 9 | 0.200 |
Why?
|
| Parasympatholytics | 1 | 2022 | 10 | 0.200 |
Why?
|
| Reducing Agents | 1 | 2022 | 3 | 0.200 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2022 | 39 | 0.200 |
Why?
|
| Piperazines | 2 | 2014 | 256 | 0.190 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2022 | 38 | 0.190 |
Why?
|
| Popliteal Artery | 1 | 2022 | 51 | 0.190 |
Why?
|
| Antiemetics | 1 | 2022 | 23 | 0.190 |
Why?
|
| Heart Atria | 1 | 2025 | 334 | 0.190 |
Why?
|
| X-Ray Diffraction | 1 | 2022 | 105 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2024 | 252 | 0.190 |
Why?
|
| Carotid Stenosis | 1 | 2023 | 135 | 0.190 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 938 | 0.190 |
Why?
|
| Vascular Patency | 1 | 2022 | 198 | 0.190 |
Why?
|
| Silver | 1 | 2022 | 30 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2023 | 252 | 0.190 |
Why?
|
| Smoking | 2 | 2024 | 944 | 0.180 |
Why?
|
| Unsafe Sex | 1 | 2021 | 24 | 0.180 |
Why?
|
| Marijuana Use | 1 | 2021 | 13 | 0.180 |
Why?
|
| Clinical Decision-Making | 4 | 2025 | 300 | 0.180 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 42 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2024 | 1420 | 0.180 |
Why?
|
| Machine Learning | 1 | 2025 | 344 | 0.180 |
Why?
|
| Aspirin | 3 | 2022 | 231 | 0.180 |
Why?
|
| Endocarditis, Bacterial | 3 | 2009 | 137 | 0.170 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2021 | 87 | 0.170 |
Why?
|
| Vaping | 1 | 2021 | 30 | 0.170 |
Why?
|
| Bacteria | 3 | 2009 | 537 | 0.170 |
Why?
|
| Time | 1 | 2021 | 101 | 0.170 |
Why?
|
| Veterans Health | 2 | 2020 | 180 | 0.170 |
Why?
|
| Cell Survival | 2 | 2020 | 884 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2025 | 828 | 0.170 |
Why?
|
| Hydroxybenzoates | 1 | 2020 | 2 | 0.170 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2020 | 5 | 0.170 |
Why?
|
| Length of Stay | 4 | 2024 | 1393 | 0.170 |
Why?
|
| alpha-Glucosidases | 1 | 2020 | 29 | 0.170 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 48 | 0.170 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2020 | 8 | 0.170 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 80 | 0.160 |
Why?
|
| Bioprosthesis | 1 | 2021 | 117 | 0.160 |
Why?
|
| Age of Onset | 2 | 2021 | 628 | 0.160 |
Why?
|
| Radiotherapy | 1 | 2020 | 147 | 0.160 |
Why?
|
| Antifungal Agents | 1 | 2022 | 305 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2023 | 267 | 0.160 |
Why?
|
| Endocarditis | 1 | 2020 | 107 | 0.160 |
Why?
|
| In Vitro Techniques | 2 | 2013 | 961 | 0.160 |
Why?
|
| Prescriptions | 1 | 2019 | 42 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 107 | 0.160 |
Why?
|
| Texas | 6 | 2024 | 3666 | 0.160 |
Why?
|
| Incidence | 6 | 2025 | 3394 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 835 | 0.150 |
Why?
|
| Leukocyte Count | 1 | 2019 | 241 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 474 | 0.150 |
Why?
|
| Pneumonia | 2 | 2020 | 341 | 0.150 |
Why?
|
| Fluoroscopy | 1 | 2019 | 99 | 0.150 |
Why?
|
| Microcirculation | 1 | 2019 | 115 | 0.150 |
Why?
|
| Office Visits | 1 | 2019 | 78 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 484 | 0.150 |
Why?
|
| Global Health | 2 | 2024 | 622 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 470 | 0.150 |
Why?
|
| Multimorbidity | 1 | 2018 | 26 | 0.150 |
Why?
|
| Alcoholism | 1 | 2021 | 252 | 0.150 |
Why?
|
| Bisoprolol | 1 | 2018 | 12 | 0.150 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 716 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 207 | 0.150 |
Why?
|
| Atenolol | 1 | 2018 | 43 | 0.150 |
Why?
|
| Propanolamines | 1 | 2018 | 32 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2025 | 648 | 0.150 |
Why?
|
| Thinness | 1 | 2019 | 77 | 0.150 |
Why?
|
| Metoprolol | 1 | 2018 | 21 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 470 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 211 | 0.150 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 111 | 0.140 |
Why?
|
| Hemodynamic Monitoring | 1 | 2018 | 16 | 0.140 |
Why?
|
| Hospitalization | 3 | 2023 | 1921 | 0.140 |
Why?
|
| Primary Prevention | 2 | 2021 | 180 | 0.140 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2023 | 450 | 0.140 |
Why?
|
| Bayes Theorem | 1 | 2019 | 310 | 0.140 |
Why?
|
| Diabetic Angiopathies | 2 | 2021 | 72 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2020 | 278 | 0.140 |
Why?
|
| Incretins | 1 | 2018 | 24 | 0.140 |
Why?
|
| Propranolol | 1 | 2018 | 121 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 396 | 0.140 |
Why?
|
| Aortic Stenosis, Subvalvular | 1 | 2017 | 6 | 0.140 |
Why?
|
| Chest Pain | 1 | 2018 | 132 | 0.140 |
Why?
|
| Cohort Studies | 4 | 2021 | 5199 | 0.140 |
Why?
|
| Recovery of Function | 2 | 2025 | 463 | 0.140 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 498 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2017 | 28 | 0.140 |
Why?
|
| Dyslipidemias | 1 | 2020 | 246 | 0.140 |
Why?
|
| Monocytes | 1 | 2019 | 346 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 110 | 0.130 |
Why?
|
| Myocardial Bridging | 1 | 2017 | 14 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 475 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2024 | 947 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2020 | 389 | 0.130 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 25 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1310 | 0.120 |
Why?
|
| Administration, Oral | 3 | 2024 | 718 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2019 | 1584 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1838 | 0.120 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 3731 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2017 | 156 | 0.120 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 152 | 0.120 |
Why?
|
| Prospective Studies | 7 | 2017 | 6582 | 0.120 |
Why?
|
| Pericardial Window Techniques | 1 | 2015 | 5 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 25 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 2575 | 0.120 |
Why?
|
| Aorta | 1 | 2018 | 557 | 0.110 |
Why?
|
| Adolescent | 8 | 2024 | 20569 | 0.110 |
Why?
|
| Cardiology | 1 | 2019 | 521 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2020 | 893 | 0.110 |
Why?
|
| Subclavian Artery | 1 | 2014 | 72 | 0.100 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2013 | 42 | 0.100 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 7 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2019 | 806 | 0.100 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 10 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2012 | 373 | 0.100 |
Why?
|
| Systole | 1 | 2013 | 202 | 0.100 |
Why?
|
| Bundle-Branch Block | 2 | 2023 | 37 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1193 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 244 | 0.100 |
Why?
|
| Hospitals, University | 4 | 2009 | 107 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 168 | 0.100 |
Why?
|
| Surgical Wound Infection | 2 | 2012 | 273 | 0.090 |
Why?
|
| Standard of Care | 1 | 2013 | 136 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 93 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 90 | 0.090 |
Why?
|
| Biomarkers | 3 | 2020 | 3415 | 0.090 |
Why?
|
| Nerve Block | 1 | 2013 | 67 | 0.090 |
Why?
|
| Metals | 1 | 2012 | 65 | 0.090 |
Why?
|
| Prosthesis Design | 2 | 2025 | 663 | 0.090 |
Why?
|
| Child, Preschool | 6 | 2020 | 14872 | 0.090 |
Why?
|
| Patient Selection | 3 | 2025 | 734 | 0.090 |
Why?
|
| Culture Media | 2 | 2009 | 183 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1166 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1124 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 84 | 0.080 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 227 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1849 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 651 | 0.080 |
Why?
|
| Blood Pressure Determination | 1 | 2010 | 115 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1156 | 0.080 |
Why?
|
| Consensus | 1 | 2013 | 725 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2019 | 1411 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2024 | 430 | 0.080 |
Why?
|
| Syndrome | 1 | 2012 | 1174 | 0.080 |
Why?
|
| Adenosine Diphosphate | 1 | 2009 | 54 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2013 | 779 | 0.070 |
Why?
|
| Platelet-Rich Plasma | 1 | 2009 | 18 | 0.070 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2009 | 58 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2009 | 65 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 240 | 0.070 |
Why?
|
| Young Adult | 5 | 2024 | 9920 | 0.070 |
Why?
|
| Syncope | 1 | 2009 | 53 | 0.070 |
Why?
|
| Aortography | 1 | 2009 | 195 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2009 | 169 | 0.070 |
Why?
|
| Bacterial Infections | 2 | 2009 | 329 | 0.070 |
Why?
|
| Reoperation | 2 | 2021 | 853 | 0.070 |
Why?
|
| DNA | 1 | 2013 | 1676 | 0.070 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 194 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 593 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2762 | 0.070 |
Why?
|
| Creatinine | 1 | 2009 | 418 | 0.070 |
Why?
|
| Osteomalacia | 1 | 2006 | 7 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 399 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 3041 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1473 | 0.060 |
Why?
|
| Child | 6 | 2020 | 25863 | 0.060 |
Why?
|
| Hepatitis C | 1 | 2009 | 387 | 0.060 |
Why?
|
| Frail Elderly | 1 | 2006 | 108 | 0.060 |
Why?
|
| Hip Fractures | 1 | 2006 | 74 | 0.060 |
Why?
|
| Biopsy | 1 | 2009 | 1204 | 0.060 |
Why?
|
| Hydrodynamics | 1 | 2025 | 28 | 0.060 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2004 | 9 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 631 | 0.060 |
Why?
|
| Antithrombins | 1 | 2025 | 61 | 0.060 |
Why?
|
| Serotyping | 1 | 2004 | 178 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2990 | 0.060 |
Why?
|
| Infant | 3 | 2005 | 13241 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2855 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2024 | 64 | 0.050 |
Why?
|
| Hypertension, Portal | 1 | 2004 | 81 | 0.050 |
Why?
|
| Age Distribution | 1 | 2024 | 427 | 0.050 |
Why?
|
| Ulnar Artery | 1 | 2023 | 5 | 0.050 |
Why?
|
| Intermittent Claudication | 1 | 2024 | 60 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2024 | 321 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2024 | 187 | 0.050 |
Why?
|
| Algorithms | 1 | 2010 | 1730 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2006 | 310 | 0.050 |
Why?
|
| Health Resources | 1 | 2024 | 127 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 679 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2023 | 145 | 0.050 |
Why?
|
| Verapamil | 1 | 2022 | 51 | 0.050 |
Why?
|
| Anorexia | 1 | 2002 | 23 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 49 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 127 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 6 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 116 | 0.050 |
Why?
|
| Students, Nursing | 1 | 2002 | 26 | 0.050 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 66 | 0.050 |
Why?
|
| Agriculture | 1 | 2022 | 33 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1887 | 0.050 |
Why?
|
| Jejunum | 1 | 2022 | 129 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 188 | 0.050 |
Why?
|
| Vomiting | 1 | 2022 | 110 | 0.050 |
Why?
|
| Mitral Valve Stenosis | 1 | 2021 | 38 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2002 | 74 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2022 | 165 | 0.050 |
Why?
|
| Triglycerides | 1 | 2024 | 616 | 0.050 |
Why?
|
| Heart Ventricles | 1 | 2006 | 789 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2021 | 10 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2006 | 999 | 0.050 |
Why?
|
| Rabbits | 1 | 2022 | 710 | 0.040 |
Why?
|
| Suicide, Assisted | 1 | 2001 | 11 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2025 | 1433 | 0.040 |
Why?
|
| Tobacco Use | 1 | 2021 | 31 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 51 | 0.040 |
Why?
|
| Bronchodilator Agents | 1 | 2022 | 153 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 213 | 0.040 |
Why?
|
| Apolipoproteins B | 1 | 2021 | 146 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2021 | 115 | 0.040 |
Why?
|
| Trachea | 1 | 2022 | 212 | 0.040 |
Why?
|
| Diarrhea | 1 | 2003 | 339 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 52 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2021 | 103 | 0.040 |
Why?
|
| Attitude | 1 | 2001 | 122 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2021 | 446 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 13 | 0.040 |
Why?
|
| Hydrazines | 1 | 2020 | 34 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2020 | 111 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2020 | 45 | 0.040 |
Why?
|
| Rivaroxaban | 1 | 2020 | 58 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 108 | 0.040 |
Why?
|
| Gastroenteritis | 1 | 2003 | 366 | 0.040 |
Why?
|
| Angina, Stable | 1 | 2019 | 8 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 51 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 313 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 2020 | 180 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 130 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2021 | 298 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 233 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 480 | 0.040 |
Why?
|
| Receptors, LDL | 1 | 2019 | 103 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 748 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 186 | 0.040 |
Why?
|
| Animals | 4 | 2022 | 36217 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 607 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 87 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 99 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 712 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1137 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 362 | 0.040 |
Why?
|
| Veterans | 2 | 2021 | 1784 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 573 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 839 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 41 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 1463 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2020 | 334 | 0.040 |
Why?
|
| Asia | 1 | 2018 | 125 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2020 | 401 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2020 | 824 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 609 | 0.030 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 133 | 0.030 |
Why?
|
| Students, Medical | 1 | 2002 | 363 | 0.030 |
Why?
|
| Calcium | 1 | 2022 | 1099 | 0.030 |
Why?
|
| Binding Sites | 1 | 2020 | 1378 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3869 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1019 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2018 | 181 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 565 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2018 | 168 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2002 | 722 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 76 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1714 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2019 | 415 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 277 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1730 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 2142 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 824 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 280 | 0.030 |
Why?
|
| Diet | 1 | 2021 | 1169 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 521 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Pregnancy | 1 | 2024 | 7599 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2012 | 338 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 1395 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 543 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3363 | 0.020 |
Why?
|
| Brain | 1 | 2022 | 3223 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 1469 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 173 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 522 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2009 | 273 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 2720 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2018 | 4917 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 108 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1973 | 0.010 |
Why?
|
| Family Practice | 1 | 2001 | 91 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2001 | 115 | 0.010 |
Why?
|